These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31975953)

  • 1. Ketamine for Treatment-Resistant Mood Disorders.
    Park LT; Falodun TB; Zarate CA
    Focus (Am Psychiatr Publ); 2019 Jan; 17(1):8-12. PubMed ID: 31975953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Ketamine in the Treatment of Psychiatric Disorders.
    Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD
    Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine treatment for depression: a review.
    Yavi M; Lee H; Henter ID; Park LT; Zarate CA
    Discov Ment Health; 2022; 2(1):9. PubMed ID: 35509843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
    Swainson J; McGirr A; Blier P; Brietzke E; Richard-Devantoy S; Ravindran N; Blier J; Beaulieu S; Frey BN; Kennedy SH; McIntyre RS; Milev RV; Parikh SV; Schaffer A; Taylor VH; Tourjman V; van Ameringen M; Yatham LN; Ravindran AV; Lam RW
    Can J Psychiatry; 2021 Feb; 66(2):113-125. PubMed ID: 33174760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine for depression clinical issues.
    Iqbal SZ; Mathew SJ
    Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
    Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
    Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compounded intranasal racemic ketamine for major depressive disorder: A case report.
    Ziegler L; Peters E; Wanson A; Halpape K
    Exp Clin Psychopharmacol; 2021 Dec; 29(6):750-754. PubMed ID: 33661659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
    Zhang JC; Yao W; Hashimoto K
    Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
    Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
    Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
    Kritzer MD; Mischel NA; Young JR; Lai CS; Masand PS; Szabo ST; Mathew SJ
    Ann Clin Psychiatry; 2022 Feb; 34(1):33-43. PubMed ID: 35166663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.
    Liester M; Wilkenson R; Patterson B; Liang B
    Cureus; 2024 Apr; 16(4):e57654. PubMed ID: 38707115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of ketamine in the treatment of treatment-resistant bipolar depression].
    Karakatsoulis GN; Tsapakis EM; Fountoulakis KN
    Psychiatriki; 2021 Dec; 32(Supplement I):70-81. PubMed ID: 34990382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
    Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G
    Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review.
    Boudieu L; Mennetrier M; Llorca PM; Samalin L
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.